Shubham Chatterjee – Medium

Shubham Chatterjee

Shubham Chatterjee

What is a biotech diligence?

Beyond the high-level frameworks — what are the questions of a biotech diligence? Read on!

Jun 3

What is a biotech diligence?

Jun 3

Shubham Chatterjee
in
LifeSci Beat

James Mutamba, CBO of Arrakis Therapeutics, on Biotech BD and IPO financing

Looking for more life sciences stories? Check us out at Spotify, Apple, Soundcloud, or LinkedIn

May 4, 2023

James Mutamba, CBO of Arrakis Therapeutics, on Biotech BD and IPO financing

May 4, 2023

Shubham Chatterjee
in
LifeSci Beat

Imogen Pryce, COO of R&D at Relay Therapeutics, on the Dynamo™ Platform and Portfolio Strategy

Looking for more life sciences stories? Check us out at Spotify, Apple, Soundcloud, or LinkedIn

Feb 1, 2023

Imogen Pryce, COO of R&D at Relay Therapeutics, on the Dynamo™ Platform and Portfolio Strategy

Feb 1, 2023

Shubham Chatterjee
in
LifeSci Beat

Kiersten Stead, Managing Partner of DCVC Bio, on Deep TechBio company creation

Looking for more life sciences stories? Check us out at Spotify, Apple, Soundcloud, or LinkedIn

Oct 26, 2022

Kiersten Stead, Managing Partner of DCVC Bio, on Deep TechBio company creation

Oct 26, 2022

Shubham Chatterjee
in
LifeSci Beat

Welcome to Season 2 of LifeSci Beat!

Looking for more life sciences stories? Check us out at Spotify, Apple, Soundcloud, or LinkedIn

Oct 12, 2022

Welcome to Season 2 of LifeSci Beat!

Oct 12, 2022

Shubham Chatterjee
in
LifeSci Beat

John Evans, CEO of Beam Therapeutics, on the Business of Biotech

Looking for more life sciences stories? Check us out at Spotify, Apple, Soundcloud, or LinkedIn

Jun 1, 2022

John Evans, CEO of Beam Therapeutics, on the Business of Biotech

Jun 1, 2022

Shubham Chatterjee

From Biotech to TechBio: ML-powered Drug Discovery (Part II)

A tidal wave of TechBio start-ups have emerged in the last few years, focused on transforming early-stage drug discovery. But what does the…

May 4, 2022

From Biotech to TechBio: ML-powered Drug Discovery (Part II)

May 4, 2022

Shubham Chatterjee

From Biotech to TechBio: ML-powered Drug Discovery (Part I)

A Cambrian explosion of TechBio start-ups has swept the market, with massive valuations emerging from its ML applications to drug…

May 4, 2022

From Biotech to TechBio: ML-powered Drug Discovery (Part I)

May 4, 2022

Shubham Chatterjee
in
LifeSci Beat

Dr. Ali Behbahani, General Partner at NEA, on evaluating and investing in cutting-edge life…

Looking for more life sciences stories? Check us out at Spotify, Apple, Soundcloud, or LinkedIn

Feb 13, 2022

Dr. Ali Behbahani, General Partner at NEA, on evaluating and investing in cutting-edge life…

Feb 13, 2022

Shubham Chatterjee

From Biotech to TechBio

Note: This post doubles as my Summer Associate application to DCVC (Data Collective), a terrifically exciting VC pioneering investments in…

Feb 5, 2022

From Biotech to TechBio

Feb 5, 2022

Shubham Chatterjee

Shubham Chatterjee

Wharton MS/MBA Candidate. Biotech stories @ LifeSci Beat Podcast. Passionate about next-gen biotech commercialization

Following

Help
Status
About
Careers
Press
Blog
Privacy
Terms
Text to speech
Teams